With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The agency hopes to gain data on the efficacy of BRAF targeted drugs used in sequence, and how physicians implement treatments compared to how the drugs are labelled.
